Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics – a case study and utility in regulatory justifications

References

• Ahmed T, Kollipara S, Boddu R, Bhattiprolu AK. 2023. Biopharmaceutics risk assessment-connecting critical bioavailability attributes with in vitro, in vivo properties and physiologically based biopharmaceutics modeling to enable generic regulatory submissions. AAPS J. 25(5):77. doi: 10.1208/s12248-023-00837-y.
   PubMed Web of Science ®Google Scholar
• Bermejo M, Hens B, Dickens J, Mudie D, Paixão P, Tsume Y, Shedden K, Amidon GL. 2020. A mechanistic physiologically-based biopharmaceutics modeling (PBBM) approach to assess the in vivo performance of an orally administered drug product: from IVIVC to IVIVP. Pharmaceutics. 12(1):74. doi: 10.3390/pharmaceutics12010074.
   PubMed Web of Science ®Google Scholar
• Bhattiprolu AK, Kollipara S, Ahmed T, Boddu R, Chachad S. 2022. Utility of physiologically based biopharmaceutics modeling (PBBM) in regulatory perspective: application to supersede f2, enabling biowaivers & creation of dissolution safe space. J Pharm Sci. 111 (12):3397–3410. doi: 10.1016/j.xphs.2022.09.003.
   PubMed Web of Science ®Google Scholar
• Boddu R, Kollipara S, Vijaywargi G, Ahmed T. 2023. Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions. Xenobiotica. 53(4):260–278. doi: 10.1080/00498254.2023.2238048.
   PubMed Web of Science ®Google Scholar
• Declaration of Helsinki. 2008. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA general assembly, Helsinki, Finland, June 1964, and amended by the WMA General Assembly, Seoul, Korea. [accessed 2023 Oct 01]. https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2008.pdf
   Google Scholar
• Dodd S, Kollipara S, Sanchez-Felix M, Kim H, Meng Q, Beato S, Heimbach T. 2019. Prediction of ARA/PPI drug-drug interactions at the drug discovery and development interface. J Pharm Sci. 108(1):87–101. doi: 10.1016/j.xphs.2018.10.032.
   PubMed Web of Science ®Google Scholar
• EMA. 2014. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. [accessed 2023 Oct 01]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf
   Google Scholar
• EMA. 2019. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. [accessed 2023 Oct 01]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf
   Google Scholar
• GCP, Good Clinical Practices for Clinical Research in India. 2013. Central drugs standard control organization. Ministry of Health and Family Welfare, Government of India. [accessed 2023 Oct 01]. https://rgcb.res.in/documents/Good-Clinical-Practice-Guideline.pdf
   Google Scholar
• Heimbach T, Kesisoglou T, Novakovic J, Tistaert C, Mueller-Zsigmondy M, Kollipara S, Ahmed T, Mitra A, Suarez-Sharp S. 2021. Establishing the bioequivalence safe space for immediate-release oral dosage forms using physiologically based biopharmaceutics modeling (PBBM): case studies. J Pharm Sci. 110(12):3896–3906. doi: 10.1016/j.xphs.2021.09.017.
   PubMed Web of Science ®Google Scholar
• ICMR. 2017. National ethical guidelines for biomedical and health research involving human participants. Indian Council of Medical Research. [accessed 2023 Oct 01]. https://ethics.ncdirindia.org//asset/pdf/ICMR_National_Ethical_Guidelines.pdf
   Google Scholar
• Jaiswal S, Ahmed T, Kollipara S, Bhargava M, Chachad S. 2021. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets. Drug Dev Ind Pharm. 47(5):778–789. doi: 10.1080/03639045.2021.1934870.
   PubMed Web of Science ®Google Scholar
• Kollipara S, Ahmed T, Bhattiprolu AK, Chachad S. 2021. In vitro and in silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: comparison among various regulatory agencies. Biopharm Drug Dispos. 42(7):297–318. doi: 10.1002/bdd.2292.
   PubMed Web of Science ®Google Scholar
• Kollipara S, Ahmed T, Praveen S. 2023a. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors. Xenobiotica. 53(5):366–381. doi: 10.1080/00498254.2023.2250856.
   PubMed Web of Science ®Google Scholar
• Kollipara S, Ahmed T, Praveen S. 2023b. Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers. Xenobiotica. 53(5):339–356. doi: 10.1080/00498254.2023.2246153.
   PubMed Web of Science ®Google Scholar
• Kollipara S, Bhattiprolu AK, Boddu R, Ahmed T, Chachad S. 2023c. Best practices for integration of dissolution data into physiologically based biopharmaceutics models (PBBM): a biopharmaceutics modeling scientist perspective. AAPS PharmSciTech. 24(2):59. doi: 10.1208/s12249-023-02521-y.
   PubMed Web of Science ®Google Scholar
• Kollipara S, Boddu R, Ahmed T, Chachad S. 2022. Simplified model-dependent and model-independent approaches for dissolution profile comparison for oral products: regulatory perspective for generic product development. AAPS PharmSciTech. 23(1):53. doi: 10.1208/s12249-021-02203-7.
   PubMed Web of Science ®Google Scholar
• Loisios-Konstantinidis I, Cristofoletti R, Fotaki N, Turner DB, Dressman J. 2020. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: naproxen. Eur J Pharm Sci. 143:105170. doi: 10.1016/j.ejps.2019.105170.
   PubMed Web of Science ®Google Scholar
• Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. 2006. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm. 309(1–2):44–50. doi: 10.1016/j.ijpharm.2005.10.044.
   PubMed Web of Science ®Google Scholar
• Pepin XJH, Parrott N, Dressman J, Delvadia P, Mitra A, Zhang X, Babiskin A, Kolhatkar V, Suarez SS. 2021. Current state and future expectations of translational modeling strategies to support drug product development, manufacturing changes and controls: a workshop summary report. J Pharm Sci. 110(2):555–566. doi: 10.1016/j.xphs.2020.04.021.
   PubMed Web of Science ®Google Scholar
• Pepin XH, Flanagan TR, Holt DJ, Eidelman A, Treacy D, Rowlings CE. 2016. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets. Mol Pharm. 13(9):3256–3269. doi: 10.1021/acs.molpharmaceut.6b00497.
   PubMedGoogle Scholar
• Rebeka J, Jerneja O, Igor L, Boštjan P, Aleksander B, Simon Z, Albin K. 2019. PBPK absorption modeling of food effect and bioequivalence in fed state for two formulations with crystalline and amorphous forms of BCS 2 class drug in generic drug development. AAPS PharmSciTech. 20(2):59. doi: 10.1208/s12249-018-1285-8.
   PubMed Web of Science ®Google Scholar
• USFDA. 2020. The use of physiologically based pharmacokinetic analyses—biopharmaceutics applications for oral drug product development, manufacturing changes, and controls. [accessed 2023 Oct 01]. https://www.fda.gov/media/142500/download
   Google Scholar
• USP. 2011. The united states pharmacopeial convention, dissolution chapter 711. [accessed 2023 Oct 01]. https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/stage_6_monograph_25_feb_2011.pdf
   Google Scholar
• Wu D, Li M. 2022. Current state and challenges of physiologically based biopharmaceutics modeling (PBBM) in oral drug product development. Pharm Res. 40(2):321–336. doi: 10.1007/s11095-022-03373-0.
   PubMed Web of Science ®Google Scholar
• Wu D, Sanghavi M, Kollipara S, Ahmed T, Saini AK, Heimbach T. 2022. Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs. Pharm Res. 40(2):337–357. doi: 10.1007/s11095-022-03319-6.
   PubMed Web of Science ®Google Scholar
• Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, Raines K, Zhao Y, Wang M, Lin HP, et al. 2021. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the US food and drug administration for new drugs. AAPS J. 23(2):31. doi: 10.1208/s12248-021-00564-2.
   PubMed Web of Science ®Google Scholar
• Yuvaneshwari K, Kollipara S, Ahmed T, Chachad S. 2022. Applications of PBPK/PBBM modeling in generic product development: an industry perspective. J Drug Deliv Sci Technol. 69:103152. doi: 10.1016/j.jddst.2022.103152.
   Web of Science ®Google Scholar
• Zhuang X, Lu C. 2016. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 6(5):430–440. doi: 10.1016/j.apsb.2016.04.004.
   PubMed Web of Science ®Google Scholar